Skip to main content
Caplight Logo









Cytora Therapeutics Ltd.

Cytora Therapeutics Ltd.

Private
IsraelHealthcare & Life Scienceshttps://www.cytorastem.com/

Company Overview

Cytora Therapeutics Ltd. is a biotechnology company that develops allogeneic, off-the-shelf stem cell therapies derived from human oral mucosa stem cells for the treatment of chronic wounds and neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

stem cell therapyregenerative medicineallogeneic therapycell therapybiopharmaceuticalchronic wound careneurodegenerative diseaseoff-the-shelf therapydiabetic foot ulcerbiotechclinical-stage biotechhuman oral mucosa stem cellshOMSCtissue regenerationdrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cytora Therapeutics Ltd. Comparables

Compare Cytora Therapeutics Ltd. with similar companies based on industry and business-model similarity.

Cytora Therapeutics Ltd. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stempeutics Research
78%
RHEACELL GmbH & Co. KG
76%
BL Pharmtech Corp.
72%

Cytora Therapeutics Ltd. Funding Rounds

Historical fundraising activity

View Full Funding History

Access detailed round history, amounts raised, valuations, and investors.

Key People

Founding team and executive leadership

Jacob Zankel

Founder and Chief Operating Officer

Founding Team

Yona Geffen

Chief Executive Officer

Executive Team

Cytora Therapeutics Ltd. Investors

Notable investors and investment history

Cytora Therapeutics Ltd. investors
InvestorRounds
Israel Innovation AuthoritySeed, Grant
Tadmor GroupSeed

Cytora Therapeutics Ltd. Filings

Explore SEC and related filing metadata, where available.

Cytora Therapeutics Ltd. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Cytora Therapeutics Ltd.'s valuation, stock price, and market status.

Is Cytora Therapeutics Ltd. a public or private company?

Cytora Therapeutics Ltd. is a private company.

What is the current stock price of Cytora Therapeutics Ltd.?

Cytora Therapeutics Ltd. is a private company with no public stock price. No recent secondary market data is available.

How much is Cytora Therapeutics Ltd. worth (valuation)?

Valuation information for Cytora Therapeutics Ltd. is not publicly available.

Can I buy Cytora Therapeutics Ltd. stock?

Cytora Therapeutics Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Cytora Therapeutics Ltd.'s last funding round?

Funding round information for Cytora Therapeutics Ltd. is not publicly available.

Who are the main investors in Cytora Therapeutics Ltd.?

Investor information for Cytora Therapeutics Ltd. is not publicly disclosed.

Will Cytora Therapeutics Ltd. IPO soon?

No public IPO plans have been announced for Cytora Therapeutics Ltd..

How can I track Cytora Therapeutics Ltd. secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Cytora Therapeutics Ltd.'s secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIsrael
Employee Range11
Year Founded2018
Last Funding—

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?